{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:00:31Z","timestamp":1772751631018,"version":"3.50.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T00:00:00Z","timestamp":1413158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0109756","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T18:00:25Z","timestamp":1413223225000},"page":"e109756","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4"],"prefix":"10.1371","volume":"9","author":[{"given":"Maxim L.","family":"Bychkov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine E.","family":"Gasparian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry A.","family":"Dolgikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail P.","family":"Kirpichnikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,10,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"A Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","article-title":"Apo2L\/TRAIL and its death and decoy receptors","volume":"10","author":"HN LeBlanc","year":"2003","journal-title":"Cell Death Differ"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"18099","DOI":"10.1073\/pnas.0507329102","article-title":"Preligand assembly domain-mediated ligand independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis","volume":"102","author":"L Clancy","year":"2005","journal-title":"PNAS"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1128\/MCB.00520-06","article-title":"Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2","volume":"26","author":"D Merino","year":"2006","journal-title":"Mol Cell Biol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1021\/bi992242l","article-title":"A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L\/TRAIL","volume":"39","author":"SG Hymowitz","year":"2000","journal-title":"Biochemistry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s10495-009-0349-3","article-title":"Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5","volume":"14","author":"ME Gasparian","year":"2009","journal-title":"Apoptosis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2005.05656.x","article-title":"Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death","volume":"130","author":"GV Georgakis","year":"2005","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.4049\/jimmunol.162.5.2597","article-title":"Functional analysis of TRAIL receptors using monoclonal antibodies","volume":"162","author":"TS Griffith","year":"1999","journal-title":"J Immunol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"28189","DOI":"10.1074\/jbc.M704210200","article-title":"Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding","volume":"282","author":"L Bin","year":"2007","journal-title":"J Biol Chem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/1535-7163.MCT-08-0918","article-title":"Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib","volume":"8","author":"TA Luster","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.cdd.4401649","article-title":"Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1","volume":"12","author":"M MacFarlane","year":"2005","journal-title":"Cell Death Differ"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1074\/jbc.M410660200","article-title":"Receptor selective mutants of apoptosis-inducing ligand 2\/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling","volume":"280","author":"RF Kelley","year":"2005","journal-title":"J Biol Chem"},{"key":"ref13","first-page":"837","article-title":"Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr. Opin","volume":"22","author":"A Yang","year":"2010","journal-title":"Cell Biol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4161\/cbt.7.2.5335","article-title":"Modulation of death receptors by cancer therapeutic agents","volume":"7","author":"HA Elrod","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ctrv.2008.11.006","article-title":"TRAIL receptor signalling and modulation: Are we on the right TRAIL","volume":"35","author":"D Mahalingam","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-10-2252","article-title":"Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents","volume":"71","author":"C Menke","year":"2011","journal-title":"Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.critrevonc.2012.08.001","article-title":"Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells","volume":"85","author":"LH de Wilt","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref18","first-page":"1112","article-title":"Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase\/Akt pathway","volume":"284","author":"KF Chen","year":"2009","journal-title":"J Biol Chem"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1158\/1078-0432.CCR-07-0251","article-title":"Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis","volume":"13","author":"R Koschny","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1535-7163.MCT-09-0918","article-title":"Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways","volume":"9","author":"N Seki","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1158\/1535-7163.MCT-07-0167","article-title":"TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib","volume":"6","author":"J Voortman","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10495-006-0025-9","article-title":"Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis","volume":"12","author":"E Saulle","year":"2007","journal-title":"Apoptosis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/sj.leu.2401812","article-title":"Protease inhibitor induced apoptosis: accumulation of wt p53, p21WAF1\/CIP1, and induction of apoptosis are independent markers of proteasome inhibition","volume":"14","author":"WG An","year":"2000","journal-title":"Leukemia"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1196\/annals.1339.042","article-title":"The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L\/TRAIL-mediated apoptosis","volume":"1059","author":"AD Brooks","year":"2005","journal-title":"Ann NY Acad Sci"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1158\/0008-5472.CAN-06-3254","article-title":"The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines","volume":"67","author":"SJ Strauss","year":"2007","journal-title":"Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-9966-29-8","article-title":"Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types","volume":"29","author":"X Ling","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1172\/JCI6863","article-title":"Disruption of p53 in human cancer cells alters the responses to therapeutic agents","volume":"104","author":"F Bunz","year":"1999","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pep.2011.04.005","article-title":"Strategy for improvement of enteropeptidase efficiency in tag removal processes","volume":"79","author":"ME Gasparian","year":"2011","journal-title":"Protein Expr Purif"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.1074\/jbc.M112.448209","article-title":"Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor 1","volume":"288","author":"B van de Kooij","year":"2013","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/MCB.22.1.207-220.2002","article-title":"Molecular ordering of the initial signaling events of CD95","volume":"22","author":"A Algeciras-Schimnich","year":"2002","journal-title":"Mol Cell Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bcp.2008.07.041","article-title":"Cathepsins: key modulators of cell death and inflammatory responses","volume":"76","author":"S Conus","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"11923","DOI":"10.1074\/jbc.M508533200","article-title":"PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells","volume":"281","author":"BH Yeung","year":"2006","journal-title":"J Biol Chem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"28960","DOI":"10.1074\/jbc.M705671200","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins","volume":"282","author":"NW Werneburg","year":"2007","journal-title":"J Biol Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00432-005-0053-9","article-title":"Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells","volume":"132","author":"NS Nagaraj","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1038\/cddis.2013.19","article-title":"Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects","volume":"4","author":"R Yu","year":"2013","journal-title":"Cell Death Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1038\/sj.onc.1209516","article-title":"Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo","volume":"25","author":"P Marini","year":"2006","journal-title":"Oncogene"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0109756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T06:56:02Z","timestamp":1689576962000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0109756"}},"subtitle":[],"editor":[{"given":"Stacey A.","family":"Rizza","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,13]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0109756","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,13]]}}}